| INTRODUCTION
Melanin is the major cellular component observed in many species of animals, plants, fungi, and bacteria. [1] In humans, it is responsible for skin color and protection against radiation. [2] However, abnormal accumulation of melanin induces pigmentation disorders, among which, the most deadly form of skin cancer can form (i.e., melanoma). [3] Melanin develops in pigment cells called melanocytes due to the overproduction of melanin, the protective tanning pigment in the skin. [4] Melanin biosynthesis is conducted in melanocytes, found in the basal layer of the epidermis and controlled by a binuclear copper enzyme called tyrosinase (TYR) (EC 1.14.14.1). [5] TYR is ubiquitous and catalyzes the oxidation of both monophenols (cresolase or monophenolase activity) and o-diphenols (catecholase or diphenolase activity) into reactive o-quinones. In addition, it is a rate-limiting enzyme for controlling the production of melanin. The melanogenesis begins with the conversion of the amino acid L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA) catalyzed by tyrosinase (TYR). [6] Therefore, the regulation of the TYR activity is directly connected with melanin biosynthesis. TYR is classified structurally as a type-3 copper protein in which each active-site copper ion is co-ordinated by three histidine residues [7] (Figure 1 ). In general, the TYR inhibition mechanism is frequently based on both specific TYR inhibitors and specific TYR inactivators. [8] A large set of potent TYR inhibitors from natural and synthetic resources have been reported during the last few years. [8] [9] [10] [11] [12] Kojic acid (KA) is a wellknown TYR inhibitor and is widely used as a popular cosmetic skin-lightening ingredient. Its capacity to chelate copper ion at the active site of the enzyme may consistently explain its inhibitory effect. [13] However, it only showed slight inhibitory activity against pigmentation within intact melanocytes or in clinical assays. [14] Therefore, it remains necessary to find new TYR inhibitors with higher activity and without off target side-effects. Dihydropyrano [3,2-b] chromenediones (DHPCs), which are considered 4H-chromenes, are an important class of fused oxygenated heterocycles that are synthesized via a one-pot three-component reaction of kojic acid, an aldehyde and a 1,3-dione [15] (Figure 2 ). These heterocyclic compounds display considerable structural diversity, including a strategic alcoholic hydroxyl functional group (-CH 2 OH), which in turn can be modified by attaching biological functional groups to develop more potent drug molecules. Interestingly, 4H-chromene derivatives present a wide range of biological properties, such as fungicidal, [16] antitumor, [17] antibacterial, [18] antidepressant, [19] antioxidative, [20] and antihypertensive [21] activity.
In this study, we report the synthesis (including X-ray characterization), inhibitory effect and computational modeling of dihydropyrano [3,2-b] 
| TYR activity
TYR-inhibition activity of the DHPC01-04 compounds (Table 1 ) was performed using L-DOPA as a substrate according to Kubo and co-workers [22] with slight modification. Incubation was carried out at 160 μl of different concentrations of the substrate L-DOPA, 20 μl (2.4 U) of enzyme mushroom tyrosinase, 20 μl of KA and different concentrations of DHPCs (25, 50 , and 100 μm). All solutions were prepared in Phosphate Buffered Saline (PBS) pH 7.2. The reaction was initiated by addition of enzyme to all wells simultaneously, which was measured over the first 5 min in the microplate reader (ELx800, BioTek) with a 490 nm filter. Furthermore, a control reaction was also performed by incubating the enzyme with KA or DHPCs in the absence of the substrate to demonstrate that there was no variation in absorbance over time. where Y, X and I denotes average absorbance change per minute, concentration of L-DOPA and concentration of DHPCs, respectively. The parameter α determines mechanism, its value determines the degree to which the binding of inhibitor changes the affinity of the enzyme for substrate.
| Computational section

| Molecular docking
The crystal structure of tyrosinase from Agaricus bisporus (AbTYR) was used as the initial point for computational procedures, it was obtained from the Protein Data Bank (PDB) under code 2Y9X, [23] which contains tropolone (TRO) as a crystal inhibitor. To validate the protocol and computational program used for molecular docking simulations for the proposed inhibitors, the crystal inhibitor (TRO) was redocked in the active site of TYR. Then, the KA and DHPCs derivatives were submitted for docking calculations. The molecular docking procedures were performed using the Molegro Virtual Docker (MVD) program. [24] It has two docking search algorithms; MolDock Optimizer and MolDock SE (Simplex Evolution). The first is the default search algorithm in MVD, [25] which is based on an evolutionary algorithm. However, MolDock SE performs better on some complexes where the standard MolDock algorithm fails. [26] Accordingly, for previous computational analysis performed for TYR systems, the MolDock SE can be applied with success for this type of complex. [27] The default parameters for the search algorithm were used to carry out molecular docking analysis. The detailed theory behind the MVD program and its characteristics are described elsewhere. [24, 27] 3 | RESULTS AND DISCUSSION
| 4H-Chromene analogs synthesis
The synthesis of the dihydropyrano[3,2-b]chromenediones was successfully achieved by employing principles of "green chemistry", and these included inexpensive off-the-shelf catalysts, short reaction times, solvent-free conditions, straightforward work-up, and good-to-high yielding syntheses. [28] For this study, DHPCs were prepared in racemic form (mixture of enantiomers) via a three-component condensation reaction of an aromatic aldehyde, dimedone, and KA. [28] To synthesize DHPC03 and DHPC04, chlorokojic acid [29] was used instead (Scheme 1). All compounds were fully characterized by 1 H NMR, 13 C NMR, IR, HRMS and in some cases X-ray crystallography (see SI file).
| Experimental kinetic assays and inhibition
The kinetic analysis was determined from the equation of the Lineweaver-Burk to obtain the inhibition constant (K i ). The kinetic parameters showed that DHPC01 had a lower effect in TYR activity, and therefore, DHPC01 did not appear to inhibit mushroom TYR. Whereas, TYR activity was prominently inactivated by DHPC02, DHPC03, and DHPC04. The kinetic analysis showed that the value of V max remained the same and the value of K m increased with increasing inhibitor concentrations, indicating that these molecules induced competitive inhibition (Figure 3 ). DHPC substrates might directly bind to the copper at the active site and thus compete with the L-DOPA substrate during catalysis. Analysis of these kinetics parameters show that the K i values of three compounds were 6.00, 9.00, and 4.00 μm for DHPC02, DHPC03, and DHPC04, respectively (see Table 1 ). Therefore, these results show high rates of inhibition of TYR and the order appears to be DHPC04 > DHPC02 > DHPC03.
The increase in the slope of the graph 1/[S] indicated the binding strength of the competitive inhibitors. That is, the slope of the graph is increased by the factor (1 + [I]/K i ) in the presence of the inhibitor. The kinetic analysis showed that these inhibitors have a single inhibition site, possibly with small differences in the docking site. Alternatively, these inhibitors can bind in multiple orientations within the catalytic site of the enzyme, giving an unexpected interactions, which may reflect small differences in inhibitor affinities.
The high slope value in the analysis of the variation in K m as a function of inhibitor concentration: 22.12 ± 1.98 and r 2 = .98 for DHPC02; 19.92 ± 1.37 and r 2 = .99 for DHPC03; and 42.19 ± 7.58 and r 2 = .94 for DHPC04 (see Fig. S4 ), suggests that these compounds have a single inhibition site of inhibition. Finally, these findings quite reasonably suggest that the DHPC compounds bind to the same binding site as the substrate L-DOPA. The results match the values of affinity enzyme-inhibitor (K i ) and the values of free interaction energy. It is therefore likely that these inhibitors present kinetic parameters that show similar features derived from inhibitors with chelating and competitive properties. [30] 
| Molecular modelling analysis
Molecular docking techniques have successfully been used to propose the bind mode and interactions occurring between the TYR enzyme and some potential inhibitors, such as, isophthalic acid, [30] hesperetin, [31] oxymatrine, [32] hydroxy-based thymol analogs, [33] KA, and KA analogs. [27] In this sense, we have performed similar analyses using the DHPC compounds derived from chemical synthesis. To validate the molecular docking procedure, and the MVD program, a redocking calculation was computed using the crystal inhibitor (TRO) as a reference. Thus, comparing theoretical and experimental complexes (TYR-TRO) revealed excellent agreement between theoretical and experimental models. In this way, this molecular docking procedure was used to compute the favored conformation of the DHPC compounds in the binding site of the AbTYR. According to the redocking results, the TRO conformation obtained by molecular docking was in good agreement with its crystal structure conformation (see Fig. S1 ). Furthermore, the DHPC compounds were also submitted to the same molecular docking steps. Our results showed that these compounds are complexed to the same binding pocket of the TRO inhibitor (see Fig. S2 ), and that the MVD program can reproduce suitable conformations for molecular like KA and DHPC compounds in complex with the TYR enzyme.
During the synthesis of the DHPC compounds, two enantiomers were obtained for each KA derivative (R and S). However, it is not clear at this stage which enantiomer is responsible for the TYR activity during kinetic analysis. To elucidate this aspect, molecular docking calculations using both enantiomers for all the DHPC compounds were undertaken. This information was taken into account with respect to the binding affinity values, and the interactions between the compounds and the amino acids residues of TYR.
The binding affinity values obtained through the MOLDOCK scoring function showed better affinity for the R enantiomer in all cases ( Table 1 ). The binding affinity values for the S enantiomers are provided in the SI file. The orientation of the aryl group for this conformation allowed suitable interactions with part of TYR enzyme (Figure 4a ). As the aryl group for the S enantiomer was exposed to solvent the interaction with the residues of TYR disappeared (Figure 4b ). Comparing KA with the DHPC compounds, all molecules interacted directly with one copper ion in the catalytic site of TYR as well as the TRO inhibitor ( Figure 5 ), which supported the competitive inhibition proposal. Considering that DHPC04 had the strongest TYR inhibitory effect, our discussion at this point will be focused around this facet, although, it is representative of all other DHPC compounds.
According to a previous computational analysis, the residues Met280 and Asn260 were found to be important in the first stage of inhibitor recognition, and their fixation during molecular docking and MD simulations, [30, 35] respectively.
Whether van der Waals interactions promoted by these residues are responsible is uncertain, [30, 31, 36, 37] Our molecular docking results suggest that the same van der Waals interaction can be found, where the carbamoyl group of Asn260 interacts with non-polar groups in the para position of KA and its derivatives for the R enantiomer.
Aside from the interactions promoted by the Asn260 residue, an interesting observation was the interaction between the DHPCs and the His243 residue, which could provide support for maintaining π-π interactions with the aryl ring of the DHPC compounds ( Figure 6 ). Interestingly, the DHPC compounds shown play a role in preventing the entry of the substrate into the active site. Once the aryl ring on the R enantiomer covers most of the TYR catalytic site, they maintain interactions with a loop of TYR which comprises the residues Asn242, His243, Gly244, Ala245, Val246, Val247, Gly248, Ala249, His250, Ala251, and Asn252 (Figure 4a ). At this point, it is proposed that the DHPC compounds influence the molecular behavior of this part of the TYR enzyme, by preventing the entrance and recognition of the natural substrate. All DHPC compounds showed interactions with the copper ion in the catalytic site of TYR (Figure 5b ). Moreover, van der Waals interactions were found between the aromatic groups of the DHPC compounds and residues Val247, Met256, Asn259, Phe263, and Val282 ( Figure 7) .
Finally, Table 1 summarizes the affinity energy values computed by the MVD program for the TYR-inhibitor complexes. Despite, the MOLDOCK scoring function [26] not describing the relationship between the in silico and experimental data sufficiently well, it was found that the computed values are suitable for qualitative analysis in the case when multiple orientations are observed for the same compound. It is important to clarify that in the present work, the interest was only focused on predicting the position of the analogs within the active site of tyrosinase. Furthermore, for this application it was shown herein that the docking approach using the MVD program [24] provides suitable predictions for docked structures into the active site of tyrosinase. The computed energy values suggest that compounds DHPC02 and DHPC04 exhibit the highest affinity for the TYR catalytic site, with the same tendency as KA and the TRO inhibitors, which emphasize an inhibitory activity comprising a competitive mode [as well as their interaction with one of the catalytic copper ions (Cu 2+
A)]. These results suggest that the binding site occupied by the DHPC compounds are very close to that found in previous studies, [31, 35] therefore, the most probable inhibition action occurs via competition with the substrate L-DOPA in the TYR active site, which is in agreement with K i values for competitive inhibition.
| CONCLUSION
The inhibitory effect of various DHPC compounds was investigated against the TYR enzyme, which was found to induce changes in k m . This is consistent with competitive inhibition interactions with the substrate (L-DOPA) at the active site. Correspondingly, changes in V m indicated binding of the test compounds provided very effective inhibition of TYR in a competitive inhibitory manner. The inhibitory mechanism of such compounds is in accordance with the copper ion chelator concept, in that, analogs to kojic acid compete with L-DOPA in the active site, which induces changes in the hydrophobic surfaces. Therefore, a combination of inhibition kinetics and computational modeling may facilitate new potential TYR inhibitors and the prediction of their inhibitory mechanisms, as shown in the present study. Further biological evaluation of DHPCs and detailed toxicity studies are ongoing and will be reported in due course.
F I G U R E 7 Van der Waals interactions
between the DHPC04 compound and TYR residues. Carbon atoms of DHPC04 are in cyan color. The same interactions have been found for the others DHPC R enantiomers. In 2D scheme, colored dash circles represent van der Waals interactions; dashed line indicates copper ion chelated by carbonyloxygen atom [Colour figure can be viewed at wileyonlinelibrary.com]
